AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02466737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB versus completion ALND
Description: in cases with 1-3 macrometastases in sentinel lymph nodes
Study NCT02769481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: 20 mg, tablet
Study NCT02769481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Bexagliflozin
Description: inactive tablet to match active comparator bexagliflozin
Study NCT03210181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
Study NCT03210181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive an equivalent volume of normal saline
Study NCT02981810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*
Description: The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55\* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
Study NCT02981810 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Study NCT01753804 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
Study NCT02320318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant 10 mg
Description: Oral tablet, once daily.
Study NCT02320318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
Study NCT02495012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Freeze-dried powder without snake venom will be dissovled in saline
Study NCT02495012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anfibatide
Description: Freeze-dried powder with snake venom will be dissovled in saline
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication intervention
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling intervention
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT01982058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Study NCT01464723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
Study NCT01778777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Universe Reverse Prosthesis
Description: Implantation of an universe reverse prosthesis
Study NCT01336569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol maleate 0.5% fixed combination
Study NCT03005938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position.
Study NCT03005938 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imitation of the spinal manipulation
Description: Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
Study NCT01743456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted intra-operative depth of anaesthesia
Description: The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
Study NCT03944434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: ribociclib 600 mg/day orally
Study NCT03944434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors, non steroideal
Description: letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
Study NCT03944434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Description: Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
Study NCT04042467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greenlight Plus
Description: Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text-messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
Study NCT04042467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight
Description: All residents and families seen in the participating clinics will receive the basic Greenlight materials.
Study NCT04042467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greenlight
Description: All residents and families seen in the participating clinics will receive the basic Greenlight materials.
Study NCT01462201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ultrasound
Description: Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
Study NCT01289704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TreSPE
Description: 1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls.
Study NCT03464058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 matching placebo tablets
Description: Oral tablets
Study NCT03557554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
Study NCT03518931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fitness testing
Description: The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
Study NCT01016561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intracavitary balloon brachytherapy
Study NCT01016561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT01016561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01016561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation
Study NCT01016561 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT01016561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01600118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: 1000 impulses
Study NCT01600118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No extracorporeal shockwave
Description: 0 impulses, acoustic effect
Study NCT01289704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TreSPE
Description: 1. treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~2. Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~3. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~4. Proprioceptive and postural kinesitherapy according to the Perfetti method.~5. Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls.
Study NCT02769481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 2, 4 or 6 mg, capsule
Study NCT02769481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Glimepiride
Description: inactive capsules to match active comparator glimepiride
Study NCT01289704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPE
Description: 1. Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~2. Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~3. Proprioceptive and postural kinesitherapy according to the neurocognitive method.~4. Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls.
Study NCT02451930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT02451930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study NCT03639675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (EYLEA, BAY86-5321)
Description: 2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
Study NCT03639675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical IOP-lowering drugs
Description: A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
Study NCT04502667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 1000U or 2000U every 24 hours orally
Study NCT04372511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binaural Beats
Description: Device: Sound with Binaural Beats at acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz with a white background noise
Study NCT03464058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Oral tablets
Study NCT04007432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulse oxymeter
Description: Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
Study NCT04353414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transmuscular Quadratus Lumborum Block
Description: Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
Study NCT04353414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular injection
Description: Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
Study NCT04353414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.
Study NCT03642743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative follow up appointment
Description: Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
Study NCT04425824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab combine with Rituximab
Description: Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).~Drug: Rituximab Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).
Study NCT02730520 — intervention group
Intervention type: OTHER
Intervention: Retrospective analysis of patient files
Description: The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
Study NCT01226043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous
Study NCT02312921 — intervention group
Intervention type: OTHER
Intervention: PREDICT
Description: Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
Study NCT01851915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 14 sessions psychological treatment for depression
Study NCT01851915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: 14 sessions psychological treatment for depression
Study NCT03267732 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegilodecakin
Description: Pegilodecakin Alone
Study NCT01244945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Description: L. reuteri will be administered at 1x10\^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10\^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10\^8 CFU/die) for 90 days.
Study NCT01244945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Placebo tabs identical in form, taste and consistency to active tabs
Study NCT02103049 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ezetimibe
Description: Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
Study NCT02296944 — intervention group
Intervention type: OTHER
Intervention: Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
Study NCT02715479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir
Study NCT02715479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS955176
Description: BMS955176
Study NCT06202456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huazhi Rougan granule
Description: Huazhi Rougan granule
Study NCT02386969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS then sham rTMS
Description: A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
Study NCT02386969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham rTMS then active rTMS
Description: A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
Study NCT04017247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intermittent oxytocin Infusion
Study NCT04017247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Continous oxytocin Infusion for 16 hours
Study NCT03622359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPECT/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
Study NCT03622359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT perfusion imaging
Description: Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
Study NCT01149811 — intervention group
Intervention type: DRUG
Intervention: Fipamezole ODT
Description: Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
Study NCT01149811 — intervention group
Intervention type: DRUG
Intervention: Fipamezole ODT Cohort 2
Description: Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
Study NCT03949985 — intervention group
Intervention type: OTHER
Intervention: Tests of biological hemostatic profile associated with contraceptives
Description: Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
Study NCT01819376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facebook Status Update
Study NCT02482207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02482207 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Life style modification
Study NCT02482207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style modification